CIK 0001799191 · Accelerated filer<br>Smaller reporting company
Starling Oncology, Inc.
Sign in to watch- Tickers
- STLN DFPH
- Exchange
- Nasdaq, OTC
- Industry
- Services-Offices & Clinics of Doctors of Medicine
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 843562323
- Phone
- 562-735-3226
- Business address
- 18000 STUDEBAKER RD, SUITE 800, CERRITOS, CA, 90703
- Former names
- Oncology Institute, Inc., DFP HEALTHCARE ACQUISITIONS CORP.
Securities
- STLN Common Stock Nasdaq
- STLNW Warrant Nasdaq
- DFPH Common stock OTC
- Open-market buys, last 90 days
- $176,273
- in 1 filing
- Open-market sales, last 90 days
- $13,322,043
- in 2 filings, $1.9M under 10b5-1 plans
Net −$13,145,770. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-17 | Podnos Yale Chief Medical Officer | Grant or award | +2,086 | 237,930 | ||
| 2025-11-17 | Carter Robert Ross Chief Financial Officer | Grant or award | +195 | 235,369 | ||
| 2025-11-12 | Virnich Daniel Chief Executive Officer | Grant or award | +6,211 | 1,793,520 | ||
| 2025-11-12 | Podnos Yale Chief Medical Officer | Grant or award | +306 | 234,642 | ||
| 2025-11-12 | Podnos Yale Chief Medical Officer | Grant or award | +1,202 | 235,844 | ||
| 2025-09-04 | M33 Growth I L.P. Director | Sale | −6,018,168 | $3.09 | $18.6M | 7,932,389 |
| 2025-09-04 | M33 Growth I L.P. Director | Sale | −681,832 | $3.09 | $2.1M | 590,892 |
| 2025-08-19 | Hively Brad Director | Sale | −20,221 | $4.06 | $82K | 622,980 |
| 2025-07-24 | BARASCH RICHARD A Director | Other disposition | −287,756 | 2,635,881 | ||
| 2025-07-22 | England Kristin Chief Administrative Officer | Grant or award | +98,037 | 98,037 | ||
| 2025-06-18 | BARASCH RICHARD A Director | Conversion | +620,400 | 2,555,541 | ||
| 2025-06-18 | BARASCH RICHARD A Director | Conversion · Class A Common Equivalent Preferred Stock | −6,204 | 0 | ||
| 2025-06-17 | BARASCH RICHARD A Director | Option exercise | +679,224 | $1.20 | $814K | 3,234,765 |
| 2025-06-17 | BARASCH RICHARD A Director | Shares withheld for taxes | −311,128 | $2.62 | $814K | 2,923,637 |
| 2025-06-17 | BARASCH RICHARD A Director | Option exercise · Common Warrant | −679,224 | 0 | ||
| 2025-06-17 | BARASCH RICHARD A Director | Conversion | +159,500 | 1,935,141 | ||
| 2025-06-17 | BARASCH RICHARD A Director | Conversion · Class A Common Equivalent Preferred Stock | −1,595 | 0 | ||
| 2025-06-05 | M33 Growth I L.P. Director | Sale | −673,676 | $3.05 | $2.1M | 13,950,557 |
| 2025-06-05 | M33 Growth I L.P. Director | Sale | −76,324 | $3.05 | $233K | 1,272,724 |
| 2025-06-03 | Hively Brad Director | Option exercise | +684,528 | $0.85 | $582K | 1,396,561 |
Page 5 of 8 · 157 trades